"Neuroblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Descriptor ID |
D009447
|
| MeSH Number(s) |
C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuroblastoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neoplasms, Neuroepithelial [C04.557.465.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.465.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.465.625.600.590.650]
- Neuroblastoma [C04.557.465.625.600.590.650.550]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Neoplasms, Neuroepithelial [C04.557.470.670]
- Neuroectodermal Tumors, Primitive [C04.557.470.670.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.470.670.590.650]
- Neuroblastoma [C04.557.470.670.590.650.550]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neoplasms, Neuroepithelial [C04.557.580.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.580.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.580.625.600.590.650]
- Neuroblastoma [C04.557.580.625.600.590.650.550]
Below are MeSH descriptors whose meaning is more specific than "Neuroblastoma".
This graph shows the total number of publications written about "Neuroblastoma" by people in this website by year, and whether "Neuroblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 |
| 1997 | 1 | 3 | 4 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 2 | 3 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 4 | 1 | 5 |
| 2003 | 3 | 1 | 4 |
| 2004 | 3 | 1 | 4 |
| 2005 | 4 | 3 | 7 |
| 2006 | 0 | 3 | 3 |
| 2007 | 4 | 1 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 7 | 0 | 7 |
| 2010 | 9 | 0 | 9 |
| 2011 | 11 | 1 | 12 |
| 2012 | 14 | 0 | 14 |
| 2013 | 13 | 0 | 13 |
| 2014 | 13 | 1 | 14 |
| 2015 | 13 | 2 | 15 |
| 2016 | 13 | 0 | 13 |
| 2017 | 11 | 2 | 13 |
| 2018 | 5 | 2 | 7 |
| 2019 | 7 | 0 | 7 |
| 2020 | 8 | 2 | 10 |
| 2021 | 9 | 1 | 10 |
| 2022 | 6 | 0 | 6 |
| 2023 | 6 | 0 | 6 |
| 2024 | 11 | 0 | 11 |
| 2025 | 4 | 0 | 4 |
| 2026 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroblastoma" by people in Profiles.
-
Stabilized phospholipid-topotecan prodrug particles increase vascular permeability and ultrasound-enhanced neuroblastoma delivery. Int J Pharm. 2026 Oct 05; 703:127283.
-
Central Nervous System Neuroblastoma, FOXR2-Activated: A Pooled Analysis of Published Clinical Outcomes. Pediatr Blood Cancer. 2026 Sep; 73(9):e70445.
-
A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma. Clin Transl Sci. 2026 06; 19(6):e70627.
-
International neuroblastoma risk group consortium: a model of networking for rare cancers. J Natl Cancer Inst. 2026 Apr 01; 118(4):579-588.
-
Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. Clin Transl Sci. 2026 03; 19(3):e70508.
-
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2026 Jan 06; 32(1):127-134.
-
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project. JCO Glob Oncol. 2025 12; 11:e2500349.
-
Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study. Transplant Cell Ther. 2026 Feb; 32(2):199.e1-199.e12.
-
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) Project. Pediatr Blood Cancer. 2025 Nov; 72(11):e31968.
-
Data set for reporting of peripheral neuroblastic tumours: recommendations from the international collaboration on cancer reporting (ICCR). Histopathology. 2025 Sep; 87(3):343-356.